nivolumab, ipilimumab

DRUG2 trials

Sponsors

Lung Cancer Group Cologne, National Health Research Institutes, Taiwan

Conditions

Carcinoma, Non-Small-Cell LungCarcinoma, Small Cell LungHepatocellular Carcinoma (HCC)

Phase 2

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

CompletedNCT03083691

Lung Cancer Group CologneCarcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung

Start: 2017-04-13End: 2023-11-20Updated: 2024-01-17

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

CompletedNCT03510871

National Health Research Institutes, TaiwanHepatocellular Carcinoma (HCC)

Start: 2019-02-12End: 2024-05-31Updated: 2024-07-08

Related Papers

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration.

2025-09-172 citations

BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMB<sup>high</sup> cohort.

Journal of Clinical Oncology2024-06-011 citations

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma

BMJ Open2022-09-018 citations

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Journal of Clinical Oncology2020-02-0128 citations

BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the SCLC cohort.

Journal of Clinical Oncology2019-05-207 citations

BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the NSCLC cohort.

Journal of Clinical Oncology2019-05-202 citations